Can a smaller dose of arthritis drug tame COVID-19 lung inflammation?
NCT ID NCT04479358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a low dose of tocilizumab, a drug used for arthritis, could help hospitalized COVID-19 patients with lung inflammation who were not on a breathing machine. The goal was to see if it sped up recovery and reduced deaths. The trial was stopped early, but results may help guide dosing of this drug during shortages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medicine
Chicago, Illinois, 60637, United States